# Catabasis Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/catabasis-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.catabasis.com
- Total disclosed funding: $72M
- Latest round: Series B (Mar 31, 2015)
- Investors on record: 6

## About

Based in Massachusetts, US and founded in 2008, Catabasis Pharmaceuticals, Inc. develops a monoclonal antibody inhibitor of plasma kallikrein as a drug for patients with Hereditary Angioedema, a rare genetic disorder. Founded by Jill Milne, Ph.D., the company raised funding in 2010 and 2011 from Advanced Technology Ventures, Clarus Ventures, MedImmune Ventures, and SV Health Investors. In 2012, Catabasis Pharmaceuticals, Inc. raised funding from Muscular Dystrophy Association, and in 2013, Advanced Technology Ventures, Clarus Ventures, Lightstone Ventures, MedImmune Ventures, and SV Health Investors invested in the company. 

The company works with pharmaceutical companies, by offering the drug application for patients with hereditary angioedema and dyslipidemias. Catabasis Pharmaceuticals, Inc. develops QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that helps patients build protective protein produced by the immune system from rare genetic disorders. The pharmaceutical institutions will approach the company by checking the process and effects of the drug during the clinical trial. If accepted, pharmaceuticals will then purchase the drug and manufacture it for public consumption through drug stores.

The company generates revenue by offering their drug application intended for patients with rare genetic disorders such as hereditary angioedema and dyslipidemias to pharmaceutical institutions.

The company plans to file the new drug application for QLS-215 in 2022 and initiate a phase 1 clinical trial in late 2022.

## Funding rounds

- Series B, Mar 31, 2015, $12M — Advanced Technology Ventures, SV Health Investors, Clarus Ventures, Lightstone Ventures, ESO Fund
- Series B, Nov 15, 2013, $32M — Advanced Technology Ventures, SV Health Investors, Clarus Ventures, MedImmune Ventures, Lightstone Ventures
- Series A, Dec 13, 2011, $5.3M — Advanced Technology Ventures, SV Health Investors, Clarus Ventures, MedImmune Ventures
- Series A, Dec 8, 2010, $15M — Advanced Technology Ventures, SV Health Investors, Clarus Ventures, MedImmune Ventures
- Series A, Apr 21, 2010, $7.7M — Advanced Technology Ventures, SV Health Investors, Clarus Ventures, MedImmune Ventures

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series A, Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series B
- ESO Fund — Series B